261 related articles for article (PubMed ID: 30410017)
1. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Chin SM; Kimberlin CR; Roe-Zurz Z; Zhang P; Xu A; Liao-Chan S; Sen D; Nager AR; Oakdale NS; Brown C; Wang F; Yang Y; Lindquist K; Yeung YA; Salek-Ardakani S; Chaparro-Riggers J
Nat Commun; 2018 Nov; 9(1):4679. PubMed ID: 30410017
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier.
Bitra A; Doukov T; Croft M; Zajonc DM
J Biol Chem; 2018 Jun; 293(26):9958-9969. PubMed ID: 29720398
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.
Bitra A; Doukov T; Wang J; Picarda G; Benedict CA; Croft M; Zajonc DM
J Biol Chem; 2018 Jan; 293(4):1317-1329. PubMed ID: 29242193
[TBL] [Abstract][Full Text] [Related]
4. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.
Claus C; Ferrara-Koller C; Klein C
MAbs; 2023; 15(1):2167189. PubMed ID: 36727218
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T.
Shen X; Zhang R; Nie X; Yang Y; Hua Y; Lü P
Cancer Biother Radiopharm; 2023 Sep; 38(7):431-444. PubMed ID: 37433196
[TBL] [Abstract][Full Text] [Related]
6. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
Battin C; De Sousa Linhares A; Leitner J; Grossmann A; Lupinek D; Izadi S; Castilho A; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Stritzker J; Steinberger P
Cancer Immunol Immunother; 2023 Sep; 72(9):3029-3043. PubMed ID: 37310433
[TBL] [Abstract][Full Text] [Related]
7. FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab.
Leitner J; Egerer R; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2023; 14():1208631. PubMed ID: 37575254
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
Cohen EEW; Pishvaian MJ; Shepard DR; Wang D; Weiss J; Johnson ML; Chung CH; Chen Y; Huang B; Davis CB; Toffalorio F; Thall A; Powell SF
J Immunother Cancer; 2019 Dec; 7(1):342. PubMed ID: 31801624
[TBL] [Abstract][Full Text] [Related]
9. Costimulatory capacity of CD137 mAbs on T cells depends on elaborate CRD structures but not on blocking ligand-receptor binding.
Jin X; Yi L; Wang X; Yan Z; Wei P; Yang B; Zhang H
Eur J Immunol; 2023 Dec; 53(12):e2350493. PubMed ID: 37675596
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.
Trüb M; Uhlenbrock F; Claus C; Herzig P; Thelen M; Karanikas V; Bacac M; Amann M; Albrecht R; Ferrara-Koller C; Thommen D; Rothschield S; Savic Prince S; Mertz KD; Cathomas G; Rosenberg R; Heinzelmann-Schwarz V; Wiese M; Lardinois D; Umana P; Klein C; Laubli H; Kashyap AS; Zippelius A
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616554
[TBL] [Abstract][Full Text] [Related]
11. A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer.
Gulen AE; Rudraboina R; Tarique M; Ulker V; Shirwan H; Yolcu ES
Cancer Immunol Immunother; 2023 Nov; 72(11):3567-3579. PubMed ID: 37605009
[TBL] [Abstract][Full Text] [Related]
12. M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Xu C; Zhou X; Webb L; Yalavarthi S; Zheng W; Saha S; Schweickhardt R; Soloviev M; Jenkins MH; Brandstetter S; Belousova N; Alimzhanov M; Rabinovich B; Deshpande AM; Brewis N; Helming L
Cancer Immunol Res; 2024 Feb; 12(2):195-213. PubMed ID: 38091375
[TBL] [Abstract][Full Text] [Related]
13. CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development.
Hashimoto K
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34064598
[TBL] [Abstract][Full Text] [Related]
14. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.
Fisher TS; Kamperschroer C; Oliphant T; Love VA; Lira PD; Doyonnas R; Bergqvist S; Baxi SM; Rohner A; Shen AC; Huang C; Sokolowski SA; Sharp LL
Cancer Immunol Immunother; 2012 Oct; 61(10):1721-33. PubMed ID: 22406983
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB-4-1BBL cis-interaction contributes to the survival of self-reactive CD8
Cho E; Singh R; Han C; Kim SH; Kim KH; Park BM; Shin DH; Han S; Kim YH; Kwon BS; Nam KT; Choi BK
Cell Mol Immunol; 2023 Sep; 20(9):1077-1080. PubMed ID: 37365325
[No Abstract] [Full Text] [Related]
16. 4-1BB immunotherapy: advances and hurdles.
Singh R; Kim YH; Lee SJ; Eom HS; Choi BK
Exp Mol Med; 2024 Feb; 56(1):32-39. PubMed ID: 38172595
[TBL] [Abstract][Full Text] [Related]
17. An engineered 4-1BBL fusion protein with "activity on demand".
Mock J; Stringhini M; Villa A; Weller M; Weiss T; Neri D
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):31780-31788. PubMed ID: 33239441
[TBL] [Abstract][Full Text] [Related]
18. Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.
Salek-Ardakani S; Zajonc DM; Croft M
Front Immunol; 2023; 14():1228486. PubMed ID: 37662949
[TBL] [Abstract][Full Text] [Related]
19. Facile generation of biepitopic antibodies with intrinsic agonism for activating receptors in the tumor necrosis factor superfamily.
Jhajj HS; Schardt JS; Khalasawi N; Yao EL; Lwo TS; Kwon NY; O'Meara RL; Desai AA; Tessier PM
bioRxiv; 2023 Dec; ():. PubMed ID: 38168220
[TBL] [Abstract][Full Text] [Related]
20. A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.
Sánchez J; Claus C; Albrecht R; Gaillard BC; Marinho J; McIntyre C; Tanos T; Boehnke A; Friberg LE; Jönsson S; Frances N
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1804-1818. PubMed ID: 37964753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
